US2002132825A1PendingUtilityA1

Analgesic combination of oxycodone and celecoxib

Priority: Sep 17, 1997Filed: Dec 27, 2001Published: Sep 19, 2002
Est. expirySep 17, 2017(expired)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 29/02A61P 25/00A61P 25/04A61K 31/54A61K 45/06A61K 31/135A61K 31/4353A61K 31/137A61K 31/485A61K 31/415
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a pharmaceutical composition, comprising a combination of a dose of celecoxib or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of celecoxib or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof such that the dosing interval of the celecoxib overlaps with the dosing interval of the oxycodone, said combination in an amount sufficient to provide an analgesic effect in a human patient.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         30 . A pharmaceutical composition comprising an analgesic combination consisting essentially of celecoxib and oxycodone.  
     
     
         31 . The pharmaceutical composition according to  claim 30 , wherein the oxycodone would be sub-therapeutic if administered without the celecoxib.  
     
     
         32 . The pharmaceutical composition according to  claim 30 , wherein the oxycodone and celecoxib are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.  
     
     
         33 . The pharmaceutical composition according to  claim 30 , which is selected from the group consisting of a tablet; a multiparticulate formulation for oral administration; a solution, a suspension or elixir for oral administration; an injectable formulation; an implantable device; a topical preparation; a suppository; a buccal tablet; and an inhalation formulation.  
     
     
         34 . The pharmaceutical composition according to  claim 30 , which is a solid oral dosage form selected from the group consisting of a tablet and a capsule.  
     
     
         35 . The pharmaceutical composition according to  claim 30 , wherein the ratio of oxycodone to celecoxib is from about 0.001:1 to about 10:1.  
     
     
         36 . The pharmaceutical composition according to  claim 30 , wherein the celecoxib synergistically potentiates the effect of the oxycodone but the oxycodone does not synergistically potentiate the effect of the celecoxib.  
     
     
         37 . The pharmaceutical composition according to  claim 34 , wherein the oral solid dosage form includes a sustained release carrier which causes the sustained release of the celecoxib, the oxycodone, or both the oxycodone and the celecoxib when the dosage form contacts gastrointestinal fluid.  
     
     
         38 . A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of celecoxib and oxycodone such that the dosing interval of the celecoxib overlaps with the dosing interval of the oxycodone.  
     
     
         39 . The method of  claim 38 , wherein the celecoxib and the oxycodone are administered orally.  
     
     
         40 . The method of  claim 38 , wherein the celecoxib and the oxycodone are administered in a single oral dosage form.  
     
     
         41 . The method of  claim 38 , wherein the oxycodone would be sub-therapeutic if administered without the celecoxib.  
     
     
         42 . The method of  claim 38 , wherein the celecoxib is administered before, simultaneously with, or after administration of the oxycodone, such that the dosing interval of the celecoxib overlaps with the dosing interval of the oxycodone.  
     
     
         43 . A method of reducing the oxycodone required to treat a patient affected with pain, comprising co-administering said oxycodone with said celecoxib to augment the analgesia attributable to said oxycodone during at least a portion of the dosage interval of said oxycodone.  
     
     
         44 . A method of reducing the amount of celecoxib required to treat a patient affected with pain comprising co-administering said celecoxib with an effective amount of oxycodone, to augment the analgesia attributable to said celecoxib during at least a portion of the dosage interval of said celecoxib.  
     
     
         45 . The pharmaceutical composition according to claim  1 , wherein the oxycodone is present in an amount from about 2.5 mg to about 800 mg.-46.  
     
     
         46 . The method of  claim 38 , wherein the oxycodone is present in an amount from about 2.5 mg to about 800 mg.  
     
     
         47 . The method of  claim 38 , wherein the ratio of oxycodone to celecoxib is from about 0.001:1 to about 10:1.

Join the waitlist — get patent alerts

Track US2002132825A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.